Efficacy and safety of secukinumab in patients with giant cell arteritis: study protocol for a randomized, parallel group, double-blind, placebo-controlled phase II trial

Efficacy and safety of secukinumab in patients with giant cell arteritis: study protocol for a randomized, parallel group, double-blind, placebo-controlled phase II trial

Abstract Background One key pathological finding in giant cell arteritis (GCA) is the presence of interferon-gamma and interleukin (IL)-17 producing T helper (Th) 1 and Th17 cells in affected arteries. There is anecdotal evidence of successful induction and maintenance of remission with the monoclon...

Full description

Bibliographic Details
Main Authors: Nils Venhoff, Wolfgang A. Schmidt, Peter Lamprecht, Hans-Peter Tony, Christine App, Christian Sieder, Carolin Legeler, Claudia Jentzsch, Jens Thiel
Format: Article
Language:English
Published: BMC 2021-08-01
Series:Trials
Subjects:
Giant cell arteritis
Secukinumab
Phase II trial
Placebo
Double-blind
Online Access:https://doi.org/10.1186/s13063-021-05520-1

Internet

https://doi.org/10.1186/s13063-021-05520-1

Similar Items